Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
$0.58
+1.8%
$0.66
$0.39
$13.98
$1.56M0.9876,811 shs14,732 shs
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
$0.06
+21.3%
$0.07
$0.03
$1.25
$2.30M0.0463,057 shs252,056 shs
OSAP
ProSomnus
$0.05
-18.1%
$0.00
$0.02
$5.10
$644K0.677,237 shs115,779 shs
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
$0.09
-41.4%
$0.06
$0.02
$1.82
$10.43M1.3957.47 million shs156.35 million shs
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
0.00%+15.51%+4.83%-26.68%-90.88%
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
0.00%+83.28%-28.57%-31.33%-91.62%
OSAP
ProSomnus
-24.46%+55.52%+4,509,900.00%+4,509,900.00%+4,509,900.00%
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
0.00%+113.03%+112.50%-41.22%-94.37%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
2.3037 of 5 stars
3.50.00.04.50.01.70.0
OSAP
ProSomnus
N/AN/AN/AN/AN/AN/AN/AN/A
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
2.00
HoldN/AN/A
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
3.00
Buy$2.504,285.96% Upside
OSAP
ProSomnus
N/AN/AN/AN/A
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
2.00
HoldN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
$250K6.24N/AN/A$1.25 per share0.46
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
$80K28.75N/AN/A($0.41) per share-0.14
OSAP
ProSomnus
$27.65M0.03N/AN/A($2.33) per share-0.02
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
$2.63M3.97N/AN/A$0.08 per share1.06

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
-$9.95M-$9.01N/AN/AN/A-218.30%-146.12%5/22/2024 (Estimated)
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
-$14.14M-$0.39N/AN/AN/AN/A-142.69%N/A
OSAP
ProSomnus
-$24.09M-$1.56N/AN/A-87.14%N/A-106.30%N/A
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
-$8.26M-$1.79N/AN/A-318.99%-81.96%-52.43%8/13/2024 (Estimated)

Latest NMRD, BJDX, SINT, and OSAP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
-$0.68-$1.78-$1.10-$1.78N/AN/A
3/27/2024Q4 2023
OSAP
ProSomnus
N/A-$0.42-$0.42-$0.42N/A$7.84 million
3/27/2024Q4 2023
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
N/A-$0.09-$0.09-$0.09N/A$0.90 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/AN/AN/AN/AN/A
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
N/AN/AN/AN/AN/A
OSAP
ProSomnus
N/AN/AN/AN/AN/A
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/A
2.26
1.82
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
N/A
0.19
0.03
OSAP
ProSomnus
N/A
1.00
0.86
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
N/A
1.84
1.60

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
18.47%
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
4.41%
OSAP
ProSomnus
70.03%
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
18.38%

Insider Ownership

CompanyInsider Ownership
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
17.60%
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
41.60%
OSAP
ProSomnus
7.70%
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
1.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
102.69 million2.22 millionNot Optionable
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
3640.35 million23.57 millionOptionable
OSAP
ProSomnus
13617.39 million16.06 millionN/A
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
43122.70 million121.47 millionNot Optionable

NMRD, BJDX, SINT, and OSAP Headlines

Recent News About These Companies

Sintx Technologies, Inc. (0A8S.L)
Sintx Technologies Prices Public Offering Of $1.3 Mln Of Shares
Why Is Sintx Technologies (SINT) Stock Down 31% Today?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bluejay Diagnostics logo

Bluejay Diagnostics

NASDAQ:BJDX
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Nemaura Medical logo

Nemaura Medical

NASDAQ:NMRD
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

ProSomnus

NASDAQ:OSAP
ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California.
Sintx Technologies logo

Sintx Technologies

NASDAQ:SINT
Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.